The aims of the Neuropathology Core are: To establish a comprehensive and standardized histopathological service to research groups in the Program. ? To provide advice and expertise on neuropathological interpretation to research groups in the Program. ? To record histopathological findings and assessments in a form that is both accessible to the research groups in the Program and readily integrated with other data for the purposes of comparative analysis. ? To establish a comparative classification of human and mouse model CNS tumors. A uniform approach to histological analysis is essential to this Program. High quality methodologies and expert evaluation of preparations will enable a robust and detailed characterization of human and mouse central nervous system (CNS) tumors from across the Program. There is scope for a detailed comparative analysis at histological and molecular levels of human and mouse model CNS tumors, both within one histopathological category, e.g. primitive neuroectodermal tumors (PNETs), and across categories, e.g. PNETs versus gliomas. Histopathological analysis will be critical for validation of genetic modification in mouse model tumors, human and mouse tumor cell characterization at the immunohistochemical and molecular cytogenetic levels, and determining the effects of novel small-molecule pharmacological agents. New diagnostic approaches combining histopathological and molecular analyses will be generated by these studies, and could form the basis for patient stratification in future clinical trials of novel therapies

Public Health Relevance

An increased understanding of the development and biology of brain tumors in childhood will advance treatment of these devastating diseases. Central to such therapeutic advances will be novel diagnostic approaches that combine histopathological and molecular analyses, so that treatment can be tailored to specific characteristics in tumor cells. As part of this Program, the Neuropathology Core expects to develop such novel diagnostic approaches for a range of childhood brain tumors

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-S)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
St. Jude Children's Research Hospital
United States
Zip Code
Pajtler, Kristian W; Wen, Ji; Sill, Martin et al. (2018) Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas. Acta Neuropathol 136:211-226
Teitz, Tal; Fang, Jie; Goktug, Asli N et al. (2018) CDK2 inhibitors as candidate therapeutics for cisplatin- and noise-induced hearing loss. J Exp Med 215:1187-1203
Tsang, Derek S; Burghen, Elizabeth; Klimo Jr., Paul et al. (2018) Outcomes After Reirradiation for Recurrent Pediatric Intracranial Ependymoma. Int J Radiat Oncol Biol Phys 100:507-515
Shadrick, William R; Slavish, Peter J; Chai, Sergio C et al. (2018) Exploiting a water network to achieve enthalpy-driven, bromodomain-selective BET inhibitors. Bioorg Med Chem 26:25-36
Roussel, Martine F; Stripay, Jennifer L (2018) Epigenetic Drivers in Pediatric Medulloblastoma. Cerebellum 17:28-36
Waszak, Sebastian M; Northcott, Paul A; Buchhalter, Ivo et al. (2018) Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncol 19:785-798
El Nagar, Salsabiel; Zindy, Frederique; Moens, Charlotte et al. (2018) A new genetically engineered mouse model of choroid plexus carcinoma. Biochem Biophys Res Commun 496:568-574
Nimmervoll, Birgit V; Boulos, Nidal; Bianski, Brandon et al. (2018) Establishing a Preclinical Multidisciplinary Board for Brain Tumors. Clin Cancer Res 24:1654-1666
Vo, BaoHan T; Kwon, Jin Ah; Li, Chunliang et al. (2018) Mouse medulloblastoma driven by CRISPR activation of cellular Myc. Sci Rep 8:8733
Wei, Lei; Murphy, Brian L; Wu, Gang et al. (2017) Exome sequencing analysis of murine medulloblastoma models identifies WDR11 as a potential tumor suppressor in Group 3 tumors. Oncotarget 8:64685-64697

Showing the most recent 10 out of 208 publications